LP97963-0
Tetrahydrogestrinone
Active
Description
The identification of tetrahydrogestrinone (THG), the first true "designer androgen," as a sports doping agent reflects both an alarmingly sophisticated illicit manufacturing facility and an underground network of androgen abusers in elite sports, as well as the still untapped potential for designer androgens in medicine. Never marketed, THG was apparently developed as a potent androgen that was undetectable by conventional International Olympic Committee-mandated urinary sports doping tests. As a potent androgen and progestin with unspecified contaminants, its distribution for use at high doses without any prior biological or toxicological evaluation poses significant health risks. Yet this diversion of science also highlights the prospect of designer androgens for use in human medicine. Designer androgens also offer the possibility of tissue-specific effects enhancing the beneficial effects of androgens while mitigating the undesirable ones. Further developments require better understanding of the post receptor tissue selectivity of androgens, comparable to the mechanism underlying that of partial estrogen agonists (SERMs). This experience highlights the ongoing need for vigilance to detect novel drug doping strategies in order to maintain fairness and safety in elite sports. This will require the deployment of generic catch-all tests, such as sensitive and specific in vitro androgen bioassays, coupled with the development of mass spectrometry-based tests for specific doping agents. Starting from gestrinone, chemists can synthesize THG in one reaction step. PMID: 15934041, PMID: 15292520 Copyright Copyright ©2005-2009 Genome Alberta (Reference to original publication: Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009 37(Database issue):D603-610.) Source: Human Metabolome Database , Tetrahydrogestrinone
Basic Part Properties
- Part Name
- Tetrahydrogestrinone
- Part Display Name
- Tetrahydrogestrinone
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2009-11-18
- Construct for LOINC Short Name
- Tetrahydrogestrinone
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP97963-0
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| es-ES | Spanish (Spain) | Tetrahidrogestriona |
| it-IT | Italian (Italy) | Tetraidrogestrinone |
| et-EE | Estonian (Estonia) | Tetrahüdrogestrinon |
| tr-TR | Turkish (Turkey) | Tetrahidrogestrinon |
| ru-RU | Russian (Russian Federation) | Тетрагидрогестринон |
| fr-BE | French (Belgium) | Tétrahydrogestrinone |
| nl-NL | Dutch (Netherlands) | tetrahydrogestrinon |
| zh-CN | Chinese (China) | 四氢孕三烯酮 Synonyms: 四氢乙基羟基二降孕三烯炔酮; |
| el-GR | Greek (Greece) | Τετραϋδρογεστρινόνη Synonyms: Τετραϋδρογεστρινόνη |
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://